TORONTO, Sept. 22, 2020 — Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a consumer packaged goods company in the cannabis products market, is thrilled to announce that its wholly owned subsidiary, KGK Science Inc. (“KGK”) has received its second Cannabis Research Licence from Health Canada pursuant to the Cannabis Act. This licence permits KGK to administer cannabis extracts, edible cannabis and cannabis topicals to human subjects for purposes of palatability and sensory testing at its clinical research facility located in London, Ontario.
Sensory evaluation measures, analyzes and interprets the reaction of human subjects to products as perceived by the senses, it is an incredibly valuable tool in understanding and determining consumer preferences and the basis for those differences. As the cannabis industry continues to expand and new products are being introduced to the market, KGK will be able use their existing database of over 25,000 participants to provide palatability and sensory studies to all licenced producers across Canada that are seeking to undertake controlled focus groups on any cannabis product development initiatives.
Hugo Alves, CEO of Auxly stated: “This exciting and strategic milestone further expands and establishes KGK’s presence and leadership role in the cannabis industry. Their remarkable science team and commitment to ensuring safe and effective cannabis products for Canadian consumers is what continues to set them apart. We couldn’t be more proud of the KGK team!”
“Securing this license is another step towards maintaining our commitment to provide leading research to support growth in the cannabis industry,” says KGK President and CEO Najla Guthrie. “Facilitating the evaluation of cannabis products aligns with our decades of experience implementing cutting-edge clinical science to help companies bring safe and effective natural health products to market. We look forward to contributing to the success of innovative, consumer-tested cannabis products for the Canadian cannabis industry.”
ON BEHALF OF THE BOARD
“Hugo Alves“ CEO
About Auxly Cannabis Group Inc. (TSX.V: XLY)
Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.
About KGK Science Inc.
KGK Science, a wholly owned subsidiary of Auxly, is a premium contract research organization (CRO) offering high-quality clinical research trials and expert regulatory support for the nutraceutical, cannabis and hemp industries. For over 22 years, KGK has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies that move products efficiently into global markets. Equipped with state-of-the-art technologies, novel research techniques, and a seasoned team of industry experts, KGK Science remains at the forefront of its industry, consolidating scientific, clinical, commercial, and regulatory expertise with innovation and agility to serve the expanding needs of global business and consumers. Visit us at www.kgkscience.com
Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.
For investor enquiries please contact our Investor Relations Team:
Notice Regarding Forward Looking Information:
This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the Company’s execution of its product development and commercialization strategy; the anticipated benefits of KGK’s research and development initiatives; consumer preferences; political change, future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally.
A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to, whether: KGK is able to maintain the Cannabis Research Licence and its other current licences, and obtain and maintain all other necessary governmental and regulatory authorizations and permits to conduct business; the success of KGK’s research strategies and the applicability of the discoveries made therein; and general economic, financial market, regulatory and political conditions in which the Company operates will remain the same. Additional risk factors are disclosed in the annual information form of the Company for the financial year ended December 31, 2019 dated May 13, 2020.
New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on Auxly’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party industry sources, the accuracy of which has not been verified by Auxly. The purpose of forward-looking information is to provide the reader with a description of management’s expectations, and such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this release.
The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, Auxly does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.